Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy  by Koyama, Akio et al.
Kidney International, Vol. 66 (2004), pp. 121–132
Staphylococcus aureus cell envelope antigen is a new candidate
for the induction of IgA nephropathy
AKIO KOYAMA, SAMINA SHARMIN, HIDEKO SAKURAI, YOSHIO SHIMIZU, KOUICHI HIRAYAMA,
JOICHI USUI, MICHIO NAGATA, KEIGYOU YOH, KUNIHIRO YAMAGATA, KAORI MURO,
MASAKI KOBAYASHI, KAORI OHTANI, TAKESHI SHIMIZU, and TOHRU SHIMIZU
Institute of Clinical Medicine, Department of Nephrology, University of Tsukuba, Ibaraki, Japan; Department of Nephrology,
Tokyo Medical University Kasumigaura Hospital, Ami, Ibaraki, Japan; and Institute of Basic Medicine, Department of
Bacteriology, University of Tsukuba, Ibaraki, Japan
Staphylococcus aureus cell envelope antigen is a new candidate
for the induction of IgA nephropathy.
Background. IgA nephropathy is the most common form of
glomerulonephritis worldwide. We previously reported a novel
form of glomerulonephritis with glomerular IgA deposits fol-
lowing methicillin-resistant Staphylococcus aureus (S. aureus)
infection. We investigated the role of S. aureus related antigens
in the immunopathogenesis of IgA nephropathy by producing
several monoclonal antibodies against S. aureus surface anti-
gens and determining the epitopes of deposited antigens in pa-
tients with IgA nephropathy.
Methods. Cell membrane proteins were isolated from cul-
tured S. aureus. Mouse monoclonal antibodies against these pro-
teins were generated, and their target epitopes were determined
by antibody affinity chromatography and amino acid sequence
analysis, and by monoclonal antibody screening of Escherichia
coli clones transfected with plasmids from the Lambda S. aureus
Genomic Library. Renal biopsy specimens from 116 patients
with IgA nephropathy and 122 patients with other forms of re-
nal disease were examined for glomerular antigen depositions
by immunofluorescence microscopy.
Results. The major antigen recognized by monoclonal an-
tibodies against S. aureus cell membrane was identified as
the S. aureus cell envelope antigen designated ‘probable ad-
hesin’ (ACCESSION AP003131-77, Protein ID; BAB41819.1).
In 68.1% (79/116) of renal biopsy specimens from patients
with IgA nephropathy, S. aureus cell envelope antigen was lo-
calized in the glomeruli, and the data confirmed that S. aureus
cell envelope antigen was co-localized with IgA antibody in the
glomeruli. No deposition of this antigen was detected in the
glomeruli of patients with non-immune complex deposit forms
of glomerulonephritis.
Conclusion. S. aureus cell envelope antigen is a new candidate
for the induction of IgA nephropathy.
Staphylococcus aureus (S. aureus) is both a normal and
a pathogenic constituent of the oral floras that commonly
colonize the surface of mucosal tissue and is kept in check
by the mucosal and systemic immune systems [1]. Nor-
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mal human sera routinely contain high concentrations of
IgA and IgG antibodies against S. aureus [2]. However,
S. aureus can cause postoperative wound infection, food
poisoning, catheter-associated infection, septicemia, en-
docarditis, and sometimes toxic shock syndrome [3]. S.
aureus is a unique bacterium that produces enterotoxins
that act as superantigens [4, 5]. Additionally, on its cell
surface, S. aureus displays protein A, which activates the
proliferation of B cells [6].
Most reports associating staphylococcal infection with
glomerulonephritis have emphasized two clinical forms:
Staphylococcus epidermidis (S. epidermidis) bacteremia
with infected ventriculo-jugular shunts, and S. aureus
bacteremia with endocarditis [7]. These types of glomeru-
lonephritis are caused by the deposition of immune com-
plexes composed of IgG antibody and bacterial antigens
in the glomeruli. We previously described a novel form
of glomerulonephritis with nephrotic syndrome and
rapidly progressive nephritic syndrome occurring after
methicillin-resistant Staphylococcus aureus (MRSA) in-
fection [8, 9]. This post-infection glomerulonephritis was
characterized by mesangial proliferation with various de-
grees of crescent formation, and glomerular deposition of
IgA, IgG, and C3. All patients with this form of glomeru-
lonephritis showed both rapid increases in serum IgA
and IgG levels and in specific T-cell receptor Vb+ subsets
during the course of the disease. We found small but sig-
nificant increases in the same T-cell receptor Vb+ sub-
sets in some patients with IgA nephropathy (IgAN) [10].
Although the degree of post-MRSA infection glomeru-
lonephritis was very marked, we hypothesize that this
type of glomerulonephritis is in fact a severe form of IgA-
related glomerulonephritis. IgAN is the most common
form of glomerulonephritis and is one of the major causes
of end-stage renal disease worldwide [11]. The renal sur-
vival rate at 20 years after the apparent onset of IgAN is
estimated at 60–70% [12]. IgAN is thought to be induced
by deposition of immune complexes containing IgA1 and
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unidentified antigens in glomeruli [13]. Nearly fifty per-
cent of patients with IgAN show an elevated serum IgA
level, and many potential candidate antigens that might
cause IgAN, including viruses, bacteria, and food anti-
gens, have been reported [13–16]. In the present study,
we investigated the possible role of S. aureus cell mem-
brane antigens in the pathogenesis of IgAN by producing
a series of monoclonal antibodies specific for S. aureus cell
membrane epitopes. We characterized the antigens rec-
ognized by these antibodies and examined renal biopsy
material from patients with IgAN to ascertain whether
these antigens were localized on glomeruli.
METHODS
Patients
All patients were diagnosed by renal biopsy, clin-
ical data and laboratory tests. IgAN was diagnosed
by the presence of predominant deposition of IgA in
the mesangium as observed by immunofluorescence mi-
croscopy and the proliferation of mesangial cells and ma-
trix as observed by light microscopy.
A monoclonal antibody against S. aureus cell mem-
brane antigen, whose production is described below, was
used to stain renal biopsy specimens from 116 patients
with IgAN and 122 patients with other forms of renal
disease who served as controls. Among the control pa-
tients, 76 patients were diagnosed with non-immune
complex types of renal disease: pauci-immune crescen-
tic glomerulonephritis (N = 8), non-immune complex
type of mesangial proliferative glomerulonephritis (N =
8), minimal change nephrotic syndrome (N = 19), fo-
cal segmental glomerulosclerosis (N = 8), minor lesions
(N = 19), tubulointerstitial nephritis (N = 8), and benign
nephrosclerosis (N = 6). Patients with acute glomeru-
lonephritis (N = 4), membranous nephropathy (N = 16),
membranoproliferative glomerulonephritis (N = 2), and
lupus nephritis (N = 10) were classified as having immune
complex types of renal disease. Patients with post-MRSA
glomerulonephritis (N = 4) and Henoch-Scho¨nlein pur-
pura nephritis (N = 10) were classified as having IgA-
related glomerulonephritis.
Preparation of S. aureus membrane antigens,
enzyme-linked immunosorbent assay (ELISA)
antigen and other bacterial lysates
S. aureus strain 8325 was cultured to the stationary
phase in Brain Heart Infusion medium (BHI; Difco, Bec-
ton Dickinson Co., Ltd., Cockeysville, MD), shaken at
37◦C overnight, and centrifuged at 12,000 × g at 4◦C for
30 min, followed by washing with sterilized TE buffer
(10 mM Tris-HCl+1 mM EDTA, pH 8.0). The pellet was
then suspended in 40 mL of TE buffer, and 80 lL of
lysostaphin (2 mg/mL dissolved in 20 mM NaOAC; Wako
Pure Chemical Industries, Ltd., Osaka, Japan) at 4◦C was
added. The mixtures was incubated at 37◦C for 45 min
for bacteriolysis and then was centrifuged at 28,000 × g
at 4◦C for 90 min. The precipitate was centrifuged at
100,000 × g at 4◦C for 1 hr to pellet the cell membrane
fraction and used as crude S. aureus membrane antigens.
Then, S. aureus crude membrane antigens were prepared
for ELISA antigen by the absorption of protein A with
human IgG-coated Sepharose 4B.
The other bacterial crude lysates, including Staphy-
lococcus epidermidis, Enterococcus faecalis, Enterococ-
cus gallinarum, Enterococcus casseleflarus, Enterococcus
raffinosus, Streptococcus oralis, Streptococcus pneumo-
niae, Group A Streptococcus, Group G Streptococcus,
Neisseria subflava, Escherichia coli (E. coli), Citrobacter
freundii, Klebsiella oxytoca, Klebsiella pneumoniae, En-
terobacter cloacae, Serratia mariesiens, Proteus mirabil-
lis, Pseudomonas aeruginosa, were prepared as S. aureus
strain 8325, which did not be purified for the cell mem-
brane fraction.
Preparation of mouse monoclonal antibodies against
S. aureus membrane antigens
Four-week-old BALB/c mice were immunized with
200 lg of S. aureus crude membrane antigens in Freund’s
Incomplete Adjuvant twice weekly for 3 months. After
sacrifice by heart puncture under anesthesia, spleen cells
were obtained from the immunized mice and fused with
NS1 cells by the polyethylene glycol method [17]. Af-
ter cloning hybridomas by limiting dilution, monoclonal
antibody-producing clones were obtained.
Purification of S. aureus membrane antigen epitope
A HiTrap NHS-activated column (Amersham Pharma-
cia Biotech AB) was conjugated with protein G-purified
mouse ascites containing described above prepared mon-
oclonal antibody. After washing and deactivation of
3 cycles of washing with 0.5M ethanolamine, pH 8.3, and
0.1 M acetate, 0.5 M NaCl, pH 4.0, was then washed with
20 mM PBS, pH 7.0, to adjust the pH to 7.0. The mem-
brane antigens of S. aureus, which were prepared by
the absorption of protein A with human IgG-coated
Sepharose 4B, were applied to the column. After washing
with PBS, pH 8.0, elution of the antigen was performed
with 0.15 M glycine-HCl, pH 2.0, and the pH of the elu-
ate was neutralized with 0.15 M glycin-NaOH buffer,
pH 10.0.
Western blot analysis
Crude S. aureus membrane antigens, the protein A
free antigen (ELISA antigen), protein A (Cappel, ICN
Biomedicals, Inc. Aurora, Ohio), and bacterial lysates
were size-fractionated on 12.5% sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE)
plates, transferred to nitrocellulose membranes, and re-
acted with primary and secondary antibodies. After
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washing, the nitrocellulose membranes were incubated
with ECL+PLUS (RPN 2132; Amersham Pharmacia
Biotech AB, Uppsala, Sweden) at room temperature for
60 min before photographic exposure. For characteriza-
tion of ELISA antigen, serum from the IgAN patient
was used as the primary antibody and horseradish perox-
idase conjugated (HRP) –antihuman IgG, IgA (Dako,
Glostrup, Denmark), or chicken HRP-anti-protein A
(IMMUNOSYSTEM AB, Uppsala, Sweden) were used
as the secondary antibodies. For analysis of human an-
tibodies against S. aureus membrane antigens, the sera
of patients with IgAN patients and normal control were
used as the primary antibodies, and HRP-anti-human IgA
was used as the secondary antibodies. For characteriza-
tion of mouse monoclonal antibodies against S. aureus
membrane antigens, described above prepared mouse
monoclonal antibodies against S. aureus membrane anti-
gens were used as the primary antibodies, and chicken
HRP-anti-mouse IgG (chicken IgY) (OME Concepts
Inc., Toms River, NJ, USA) was used as the secondary
antibodies. For analysis of the monoclonal antibody with
other bacteria cross-reactivity, mouse monoclonal anti-
body against S. aureus membrane antigens and mouse
IgG isotype control (Medical & Biological Laboratories
Co. Ltd, Nagoya, Japan) were used as the primary anti-
body and chicken HRP-anti-mouse IgG was used as the
secondary antibody.
Quantitative analysis of anti-S. aureus antibodies
by ELISA
IgG and IgA class antibody titers against S. aureus in
sera from various types of renal diseases and normal in-
dividuals were measured by ELISA. ELISA plates were
coated with 50 lL (5 lg/mL) of the protein A free antigen
were coated in 20 mM carbonate buffer, pH 9.8, and incu-
bated overnight at 4◦C and washed 5 times with washing
buffer (0.01M PBS, pH 8.0, plus 0.05% Tween-20 (PBS-
Tween-20). Next, 250 lL of blocking buffer (0.5% bovine
serum albumin (BSA) in PBS-Tween-20) were added to
each well, and the resulting mixture was incubated at
room temperature for 1 hour. Plates were then washed
with washing buffer. Fifty microliters of a 1/100 dilution of
serum samples were added to the wells and incubated at
37◦C for 1 hour, then washed 5 times with washing buffer.
Fifty microliters of a 1/1000 dilution of rabbit HRP-anti-
human IgA and IgG (Dako) was added to the wells
and incubated for 1 hour at 37◦C, then washed 5 times
with washing buffer. Fifty microliters of substrate ABTS
(2, 2-azino-di (3-ethylbenthiazoline) sulfonic acid Zymed
Laboratories, Inc., CA, USA) was added to the wells
and incubated at room temperature for 30 minutes, and
50 lL of stopping buffer (2 mmol/L NaN3) was added, and
then measured by an immunoreader with 405nM/540nM
filtering. The antibody titers were expressed as OD units.
Amino acid sequence analysis
Amino acid sequence analysis was performed by au-
tomated Edman degradation of peptides generated by
chemical or enzymatic cleavage of the reduced and S-
carboxymethylated protein. A homology search was car-
ried out using the BLAST database [18].
Identification of monoclonal antibody epitopes
The Lambda Zap II vector containing an S. aureus
library (RN450 strain; Stratagene, La Jolla, CA, USA)
was used to transform E. coli cells (XL1-Blue MRF’
host strain). After induction with isopropyl-1-thio-b-D-
galactopyranoside (IPTG), E. coli clones that reacted
with the monoclonal antibody described above were
screened for S. aureus membrane antigens. The plas-
mid DNA from clone was purified using a purifica-
tion kit (Gene Clean II kit; Bio 101, La Jolla, CA,
USA) and amplified by polymerase chain reaction (PCR)
with M13 primers (5′-GGAAACAGCTATGACCATG-
3′ and 5′-GTAAAACGACGGCCAGT-3′) using a dGTP
sequence kit (dGTP Big Dye Terminator; ABI Prism, PE,
Applied Biosystems, Foster City, CA, USA). The PCR
conditions were 25 cycles of denaturation at 90◦C for 10
seconds, annealing at 50◦C for 5 seconds, and extension
at 60◦C for 4 minutes. The DNA sequence of the PCR
product was analyzed with an automated DNA sequencer
(ABI 310 Genetic Analyzer; Applied Biosystems).
Antigen detection by immunofluorescent examination
of renal biopsy specimens
Renal biopsy specimens were examined by routine
light, electron, and immunofluorescence microscopy. A
portion of each specimen was frozen with n-hexane
in solid carbon dioxide-acetone for immunofluores-
cence microscopy. Frozen 4 lm tissue sections were
stained in the standard manner using mouse mono-
clonal antibody to S. aureus membrane antigen and flu-
orescein isothiocyanate-rabbit anti-mouse IgG antibody
(Sigma). To study whether S. aureus membrane anti-
gen and human IgA antibody were co-localized in re-
nal biopsy specimens, tissue sections were stained with
a mixture of mouse monoclonal antibody to S. aureus
membrane antigen and rabbit anti-human IgA (Sigma)
as primary antibodies, and with a mixture of Alexa
488-labeled goat anti-mouse IgG antibody (Molecular
Probes, Inc., Eugene, OR, USA) and Alexa 594-labeled
goat anti-rabbit IgG antibody (Molecular Probes, Inc.)
as secondary antibodies. The blocking buffer was 2%
normal goat serum in 0.05% Tween 20-PBS. As a neg-
ative control, a mouse IgG1 isotype control (Medical
& Biological Laboratories Co. Ltd.) was used. An im-
munofluorescence microscope (Olympus BX51, Olym-
pus Optical Co. Ltd., Tokyo, Japan), ORCA-1394 digi-
tal camera (Hamamatsu Photonics Co. Ltd., Hamamatsu,
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Fig. 1. Western blot analysis of S. aureus antigens. Lanes 1 and 3: crude membrane antigen. Lanes 2 and 4: antigen prepared by absorption of
protein A with human IgG-coated Sepharose 4B. Staining was with a IgA nephropathy patient’s serum (1st Ab), followed by staining with HRP-
anti-human IgG (lanes 1 and 2) or HRP-anti-human IgA (lanes 3 and 4) (2nd Ab). Lane 5: Protein A. Lane 6: crude membrane antigen. Lane 7:
antigen prepared by absorption of protein A with human IgG-coated Sepharose 4B. Lanes 5, 6 and, 7 were stained with chicken anti-Protein A.
Japan), and AQUA-Lite software (Hamamatsu Photon-
ics Co. Ltd.) were used to study antigen and antibody
co-localization.
Statistical analysis
All data were statistically analyzed by the analysis of
variance (ANOVA), the Mann-Whitney test, and the chi-
square test. A P value of less than 0.05 was considered to
be significant.
RESULTS
Characterization of crude S. aureus membrane
antigens and the antigen for ELISA
Crude S. aureus membrane antigens were prepared
from S. aureus 8325. Then, S. aureus crude membrane
antigens were purified for ELISA antigen by the absorp-
tion of protein A with human IgG-coated Sepharose 4B.
To characterize crude S. aureus membrane antigens and
ELISA antigen, immunoblot analyses were performed
(Fig. 1). In lanes 1 and 3 (crude membrane antigen),
numerous bands, ranging high to low molecular weight,
were observed. However, in lanes 2 and 4 (the antigen for
ELISA), we could not detect bands larger than 50 kD. In
lane 5 (protein A of S. aureus), a narrow band was ob-
served at 50 kD, and in lane 6 (crude membrane antigen),
a broad band, ranging 50 to 150 kD was observed. In lane
7 (antigen used in ELISA), we failed to detect any band.
Analysis of human antibodies against crude
S. aureus membrane antigens
Crude S. aureus membrane antigens were subjected
to electrophoresis, and we applied the sera of patients
with IgAN and control patients, followed by staining
with HRP-labeled anti-human IgA antibody (Fig. 2).
Upon application of sera from patients with IgAN, large
(>50 kD) and relatively small band especially 35 kD and
17 kD were frequently revealed. In contrast, when the
sera from control patients were applied, only large bands
(>50 kD) were detected.
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Fig. 3. Antibody titers to S. aureus in IgAN and other types of renal diseases by ELISA. The upper schema indicates anti-S. aureus antibodies
(IgG class). The lower schema indicates anti-S. aureus antibodies (IgA class). S: significant difference (P < 0.05). ns: not significant difference.
HSPGN: Henoch-Scho¨nlein purpura nephritis, MN: Membranous nephropathy, MPGN: menbranoproliferative GN, LN: lupus nephritis, Pauci Cr
GN: pauci-immune crescentic GN, non-IgAN: non-immune deposit mesangial proliferative GN, MCNS: minimal change nephritic syndrome, FGS:
focal glomerular sclerosis, minor: minor change, TIN: tubulointerstitial nephritis, BNS: benign nephrosclerosis. Solid circles indicate mean ± SD.
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 2. Western blot analysis in sera from patients and controls for antibodies to S. aureus membrane antigen. Crude S. aureus membrane antigen
was analyzed in each lane and probed with sera from three control subjects and three patients with IgAN, followed by staining with HRP-anti-human
IgA. In the patients with IgAN, both large molecular weight (>50 kD) and relatively smaller molecular weight bands, in particular at 35 kD (arrow
head) and 17 kD (arrow), were frequently detected. In contrast, in the three control subjects, only bands larger than 50 kD were detected.
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Quantitative analysis of anti-S. aureus antibodies
(IgG and IgA)
In order to measure the titer of anti S. aureus antibod-
ies in patients with renal diseases and normal individu-
als, ELISA analysis were performed. ELISA plates were
coated with described above ELISA antigen. Ninety-four
serum samples from patients with IgAN, 196 serum sam-
ples from patients with various types of renal diseases,
and 16 serum samples from normal individuals were ex-
amined (Fig. 3). Both IgG and IgA titers to S. aureus in the
sera from patients with IgAN and post-MRSA glomeru-
lonephritis were significantly higher than those in other
forms of renal disease and normal individuals.
Characterization of mouse monoclonal antibodies
against S. aureus membrane antigen
We generated several monoclonal antibodies against
the crude membrane antigen of S. aureus in BALB/c
mice. Five clones, S9D6 (IgG2aj), S1D7 (IgG1j), S1B9
(IgG1j), S1D6 (IgG1j), and S10D4 (IgG2bj), reacted
with a 35 kD band of S. aureus membrane antigen, and
1 clone, S9C7 (IgG2aj), reacted with a 17 kD band. The
five monoclonal antibodies reacted with the same 35 kD
S. aureus membrane antigen, based on DNA sequence
analysis of the antigen recognized by each monoclonal
antibody. One of the monoclonal antibodies that reacted
with the 35 kD band (Fig. 4), S1D6, was used as a repre-
sentative antibody in the following experiments.
Cross-reactivity of the monoclonal antibody, S1D6,
with the other bacteria
To investigate the cross-reactivity of monoclonal an-
tibody S1D6 with the other bacteria, immunoblot anal-
yses were performed (Fig. 5). The monoclonal antibody
against S. aureus membrane antigen, S1D6, cross-reacted
with only the bacterial lysates of S. epidermidis (35 kD
band), group G Streptococcus (150 kD band), and Strep-
tococcus pneumoniae (150 kD band). However, in lane
18 in which we had applied group G Streptococcus cell
lysate and stained it with mouse IgG1 isotype control, a
150 kD band was seen.
Determination of S. aureus membrane antigenic epitope
In order to determine S. aureus membrane antigenic
epitope, antigen, prepared by the absorption of protein
A with human IgG-coated Sepharose 4B, was purified
by S1D6 antibody affinity chromatography. In the anal-
ysis of SDS gels stained with coomassie G 250 (Bio-Rad
laboratories, Hercules, CA) staining, there was no 50 kD
band, and a strong 35 kD band was observed in lane 1
(the antigen prepared by the absorption of protein A
with human IgG-coated Sepharose 4B). In lane 2 (eluate
from the HiTrap affinity column), a single 35 kD band
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Fig. 4. Western blot analysis using 2 representative monoclonal anti-
bodies against S. aureus. Lane 1: crude S. aureus cell membrane antigen.
Lanes 2 and 3: antigen prepared by absorption of protein A with human
IgG-coated Sepharose. Staining was with mouse monoclonal antibody
S1D6 (IgG1-j) or S9C7 (IgG2a-j), (1st Ab), followed by staining with
HRP-anti-mouse IgG (2nd Ab). A monoclonal antibody, S1D6, reacted
with a 35 kD band of crude S. aureus cell membrane antigens, and a
clone, S9C7, reacted with a 17 kD band.
was observed. A 50 kD band was seen in lane 3 (protein
A) (Fig. 6). Amino acid sequence analysis of the eluate
from the nitrocellulose membranes was performed, re-
vealing a sequence of 20 amino acids (NVGGDNVDIH-
SIVPVGQDPH).
Characterization of S. aureus membrane
antigenic epitope
For identification of epitopes, monoclonal antibody
screening of E. coli clones transfected with plasmids from
the Lambda S. aureus genomic library was performed.
E. coli clones that reacted with monoclonal antibody
S1D6 were screened for S. aureus membrane antigens.
Immunoblot analysis showed that #26 clone reacted with
the monoclonal antibody. The clone plasmid DNA was
purified. The #26 DNA sequence was performed and a
homology search for the sequence of this antigen was
also done using the entire S. aureus genome database
and the program BLAST. The sequence was identified as
S. aureus cell envelope antigen, ‘probable adhesin’
(34.7 kD, Accession AP003131-77, Protein ID;
BAB41819.1) [18, 19]. The 20 amino acids sequence
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8. Proteus
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11. Neisseria
12. Enterococcus faecalis
13. Streptococcus pneumoniae
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16. Staphylococcus epidermidis
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Fig. 5. Cross-reactivity of monoclonal antibody S1D6 with the other bacteria. Lane 1: marker mixture. Lanes 2–17: bacterial lysates. Lane 18:
Group G Streptococcus (which was also in lane 14). Staining was with mouse monoclonal antibody S1D6 (lanes 2–17) or mouse IgG isotype control
(lane 18), followed by HRP-anti-mouse IgG (chicken).
(NVGGDNVDIHSIVPVGQDPH), determined as S.
aureus membrane antigenic epitope, was included in the
amino acid sequence of the ‘probable adhesin’ (Fig. 7).
The sequence of this protein showed high homology to
that of the S. epidermidis lipoprotein and Streptococcus
pneumoniae PsaA.
Immunofluorescent examination of renal tissues
The monoclonal antibody S1D6 was applied to renal
biopsy specimens from 116 patients with IgAN and 122
patients with other renal diseases (Table 1). The S. aureus
cell envelope antigen was detected on the glomeruli of
68.1% (79/116) of the patients with IgAN (Fig. 8B), while
it was not detected in the renal biopsy specimens from any
of the patients with non-immune complex types of renal
disease (0/76). However, this antigen was detected on the
glomeruli of some patients with other immune complex
types of glomerular disease. On the other hand, we failed
to find any antigen in the glomeruli of patients with IgAN
detected by a monoclonal antibody (S9C7) reacting with
the 17 kD band. We also showed the double-staining of
S. aureus membrane antigen and anti-human IgA anti-
body (Fig. 8C). Deposits of S. aureus membrane anti-
gen and IgA antibody are both detected in the mesangial
areas.
DISCUSSION
The major finding in this study was that deposition
of an S. aureus cell envelope antigen was detected on
the glomeruli of nearly 70% of the patients with IgAN,
by staining with a monoclonal antibody that had been
newly developed against a 35 kD antigen on the cell sur-
face of S. aureus. We characterized the antigen by both
monoclonal antibody affinity chromatography and amino
acid sequence analysis, and we identified it as the S. au-
reus cell envelope antigen, ‘probable adhesin’ (Accession
AP003131-77, Protein ID; BAB41819.1). We confirmed
the identity of the antigen by monoclonal antibody
screening of clones of E. coli transfected with plasmids
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Fig. 6. Analysis of applied antigen to the Hi-
Trap affinity column and the eluate from the
HiTrap column by SDS-PAGE and coomassie
staining. Lane 1: applied antigen, prepared
by absorption of protein A with human IgG-
coated Sepharose. Lane 2: Eluate from anti-
S. aureus antibody-coated affinity column.
Lane 3: protein A. SDS-gel was stained with
Coomassie G 250.
Fig. 7. Amino acid sequence of S. aureus cell membrane antigen. Amino acid sequence of S. aureus cell envelope antigen (34.7 kD, Accession
AP003131-77, Protein ID; BAB41819.1) was shown. The bold amino sequence was as same as the 20 amino acids of the determined S. aureus
membrane antigenic epitope form HiTrap affinity column in Fig. 6.
of a Lambda genomic library of S. aureus DNA clones
[19].
Using Western blot analyses, we also demonstrated
that 35 kD and 17 kD bands were strongly positive in
the sera from patients with IgAN. For accurate compar-
ison, we measured the titers of anti-S. aureus antibod-
ies in various types of glomerulonephritis by ELISA.
In the sera from patients with IgAN and post-MRSA
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Table 1. Glomerular deposition of S. aureus antigen
No. of patients
Antigen Antigen Percent
Diagnosisa Total positive negative positive %
IgA nephropathy 116 79 37 68.1
IgA nephropathy-related types
Post-MRSA 4 3 1 75.0
glomerulonephritis
Henoch-Scho¨nlein 10 6 4 60.0
purpura nephritis
Immune complex types
Acute glomerulonephritis 4 0 4 0.0
Membranous nephropathy 16 1 15 6.3
Membranoproliferative 2 0 2 0.0
glomerulonephritis
Lupus nephritis 10 3 7 30.0
Nonimmune complex types
Pauci-immune crescentic 8 0 8 0.0
glomerulonephritis
Non-IgA nephropathy 8 0 8 0.0
Minimal change nephrotic 19 0 19 0.0
syndrome
Focal segmental 8 0 8 0.0
glomerular sclerosis
Minor lesions 19 0 19 0.0
Tubulointerstitial nephritis 8 0 8 0.0
Benign nephrosclerosis 6 0 6 0.0
aGlomerular deposition of S. aureus membrane antigen was detected
by immunofluorescent staining with monoclonal antibody, S1D6. Fluorescein
isothiocyanate-rabbit antimouse IgG antibody was used as the secondary anti-
body.
glomerulonephritis, titers of anti-S. aureus antibodies
(IgG and IgA classes) were significantly higher than those
in other types of GN and in normal individuals. The tar-
get antigens were 35 and 17 kD antigens, and it is likely
that we detected the antibodies to same antigens by West-
ern blotting as by ELISA. These results suggest that both
35 kD and 17 kD antigens of S. aureus may have strong
immunogenicity in many patients with IgAN. Therefore,
immune complexes composed of S. aureus antigens, es-
pecially 35 and 17 kD antigens and their antibodies, may
play a role in the pathogenesis of IgAN.
We have detected colonies of S. aureus on the oral and
nasal mucosal surfaces of some patients with IgAN as well
as on normal individuals (unpublished data). According
to Kluytmans et al [3], there are three distinguishable pat-
terns of S. aureus carriage: approximately 20% of individ-
uals almost always carry one strain; a large proportion of
the population (60%) harbors S. aureus intermittently;
and the remaining 20% almost never carry S. aureus. The
mean carriage rate in the general population is 37.2%;
therefore, many people may potentially develop IgAN.
Colonization and inversion of bacteria in the blood cir-
culation are thought to be influenced by the balance be-
tween the mucosal and systemic immunities. However,
the mechanism by which S. aureus initiates colonization
of host tissues is not completely understood. S. aureus can
adhere to components of the extracellular matrix in the
host. Adherence is mediated by protein adhesins on the
surface of S. aureus; in most cases, the protein adhesins
Fig. 8. Co-localization of S. aureus envelope antigen and IgA antibody
in the glomeruli of a patient with IgA nephropathy. (A) Immunofluo-
rescence staining with rabbit anti-human IgA antibody. Predominant
mesangial depositions (green) are noted in the three glomeruli. (B) Im-
munofluorescence staining of S. aureus membrane antigen with mon-
oclonal antibody (S1D6). Deposits (red) are mainly observed in the
glomerular mesangial area. (C) Double-staining of S. aureus membrane
antigen and antihuman IgA antibody. Deposits of S. aureus membrane
antigen and IgA antibody (yellow) are observed in the mesangial areas.
This indicates the co-localization of antigen and antibody.
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are covalently anchored to the cell wall peptidoglycan
and recognize the family of adhesive matrix molecules
[20]. Our data indicate that our candidate antigen for
the pathogenesis of IgAN is the newly reported ‘prob-
able adhesin’ [19]. Fibronectin has been reported to be
present in the circulating immune complexes of patients
with IgAN [21]. However, not all patients with IgAN have
IgA-fibronectin complexes [22], and differences in the
composition of IgA immune complexes are still unclear.
In this study, we have identified the antigen that was de-
posited on the glomeruli of many patients with IgAN as
‘probable adhesin’ [19]. We believe that this antigen and
the antibodies specific for it constitute the complexes in
the circulation and that these complexes are deposited
on the glomeruli.
IgA, especially IgA1, has unique characteristics. Re-
cently, there have been many reports on the role of the
galactose-deficient hinge region of IgA1 in the pathogen-
esis of IgAN; in particular, characteristics of IgA1, such
as the instability of its structure [23, 24], self-aggregation
[25, 26], adhesion to extracellular matrix [25, 26], pro-
duction of autoantibodies (to IgG or GalNAc residual)
[27, 28], and its glomerulophilic characteristics [29] have
been reported. Considering these reports, we speculate
that S. aureus antigen-IgA1-immune complexes are eas-
ily deposited in the glomeruli, because IgA1 has these
unique characteristics.
Regarding the immunogenetic background of IgAN,
there have been reports of HLA linkage with this disease
[13]. Recently, Gharavi et al [30] reported that familial
IgAN is linked to 6q22-23. The immunologic status of pa-
tients with IgAN, especially regarding the Th1 and Th2
types, has been reported [31]. Patients with IgAN have
Th2 predominance in their peripheral Tlymphocytes and
in their cytokine profiles [32]. We speculate that these
findings are related to normal or pathological bacterial
colonization and abnormal immune response to these
antigens.
It is possible that our monoclonal antibody cross-
reacted with proteins on the cell envelope of other bac-
teria such as S. epidermidis lipoprotein and Streptococcus
pneumoniae PsaA, both of which show high homology
to this antigen. We analyzed the cross-reactivity of this
monoclonal antibody to the bacterial lysates of several
normal and pathogenic flora, including S. epidermidis and
Streptococcus pneumoniae, by the Western blot method
and found that there was no cross-reactivity of this anti-
body with the bacterial lysates of other bacteria except
for a weak 35 kD band in S. epidermidis and a strong
150 kD band in group G Streptococcus and Streptococ-
cus pneumoniae. However, when we stained the bacterial
lysate from Streptococci with mouse IgG1 isotype con-
trol by Western blot analysis, a 150 kD band was also
detected. Therefore, these 150 kD bands were thought to
be nonspecific and may represent a reaction to the pro-
tein G of Streptococci. However, at least, antigens which
were reacted with this monoclonal antibody may be target
antigens.
Suzuki et al [15] reported that Haemophilus parain-
fluenzae outer membrane antigens were deposited on
the glomeruli of patients with IgAN. Considering that
S. aureus and H. parainfluenzae are both common oral
and nasal flora, we speculate that both of these bacte-
ria contribute to the pathogenesis of IgAN. In patients
with IgAN, macroscopic hematuria frequently occurs
suddenly after upper respiratory infection. It may in-
dicate that bacterial antigens invasion occurs via in-
jured mucosal barrier soon after upper respiratory
infection, and the fragment of bacterial antigens and their
antibodies presented in the sera may form circulating im-
mune complexes, and formed immune complexes may
deposit in the glomeruli.
In order to prevent the occurrence and progression of
IgAN, new types of antibiotics that can eradicate such
bacterial colonies and that can be taken over the long-
term are needed. Presently, there are no suitable antibi-
otics for long-term prevention of S. aureus colonization
[33, 34]. Another strategy would be to develop a vac-
cine that prevents colony formation without production
of nephritogenic immune complexes [35].
For all of the reasons discussed above, it is important
to clarify the mucosal and systemic immune status and
genetic background of patients with IgAN. We demon-
strated here that in a significant number of patients with
IgAN, the antigen deposited on glomeruli was an S. au-
reus cell envelope protein, ‘probable adhesin,’ which may
originate from colonized bacteria, and that it plays a key
role in the immunopathogenesis of IgAN.
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